Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats

Frank Porreca, A. Cowan, R. J. Tallarida

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The dopaminergics, apomorphine (1 mg/kg), bromocriptine (1, 10 and 20 mg/kg), piribidel (5, 20 and 40 mg/kg) and thyrotropin releasing hormone (TRH) (1, 10 and 20 mg/kg), were each injected SC in rats at 09.00 h and 18.00 h daily for at least 20 days. Only apomorphine induced a behavioral syndrome (AIBS) in both male and female rats, characterized by tail-vibration (within 5 days) and a hyperexcitement which included defecation, mounting (in males only), jumping, cliff-jumping, climbing and, after 9-11 days, sham-boxing. Chronically-treated rats were placed, individually, in a small glass cylinder; only those rats on apomorphine displayed an increase in excitement and constant circling, almost exclusively in a counterclockwise direction. Acute pretreatment with d-butaclamol (0.64 mg/kg, SC), but not with the l-enatiomer, blocked the AIBS. No sham-boxing occurred when d-amphetamine (1 and 5 mg/kg), bromocriptine (10 and 20 mg/kg), piribidel (1, 5, 10, 20 and 40 mg/kg) and TRH (1 and 20 mg/kg) were substituted for apomorphine; in the presence of noise, substitution of piribidel (5, 10, 20 and 40 mg/kg) elicited mild displays of sham-boxing. When apomorphine (1 mg/kg) was substituted for chronically-administered bromocriptine (20 mg/kg) bidirectional circling, but no AIBS, was seen. Apomorphine, when substituted for piribidel or TRH, did not induce circling or the AIBS. Tolerance did not develop to the AIBS over 90 days; 31 days after the final injection, the AIBS could again be elicited by a single dose of apomorphine (1 mg/kg). The behavioral syndrome linked with chronic administration of apomorphine, and the associated reverse tolerance, differentiate apomorphine from the other test compounds. Nevertheless, the partial cross-sensitization between apomorphine and piribidel, and between bromocriptine and apomorphine, provides evidence of common mechanisms at the functional level. The AIBS represents an additional model that may be used in the study of dopamine receptors in vivo.

Original languageEnglish (US)
Pages (from-to)70-74
Number of pages5
JournalPsychopharmacology
Volume76
Issue number1
DOIs
StatePublished - Jan 1982
Externally publishedYes

Fingerprint

Thyrotropin-Releasing Hormone
Bromocriptine
Apomorphine
Boxing
Butaclamol
Dextroamphetamine
Defecation
Dopamine Receptors
Vibration

Keywords

  • Apomorphine
  • Bromocriptine
  • Chronic administration
  • Piribidel
  • Reverse tolerance
  • Sham-boxing
  • Tail-vibration
  • TRH

ASJC Scopus subject areas

  • Pharmacology

Cite this

Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats. / Porreca, Frank; Cowan, A.; Tallarida, R. J.

In: Psychopharmacology, Vol. 76, No. 1, 01.1982, p. 70-74.

Research output: Contribution to journalArticle

@article{78b2741326d840eb9f0a04d298c903bd,
title = "Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats",
abstract = "The dopaminergics, apomorphine (1 mg/kg), bromocriptine (1, 10 and 20 mg/kg), piribidel (5, 20 and 40 mg/kg) and thyrotropin releasing hormone (TRH) (1, 10 and 20 mg/kg), were each injected SC in rats at 09.00 h and 18.00 h daily for at least 20 days. Only apomorphine induced a behavioral syndrome (AIBS) in both male and female rats, characterized by tail-vibration (within 5 days) and a hyperexcitement which included defecation, mounting (in males only), jumping, cliff-jumping, climbing and, after 9-11 days, sham-boxing. Chronically-treated rats were placed, individually, in a small glass cylinder; only those rats on apomorphine displayed an increase in excitement and constant circling, almost exclusively in a counterclockwise direction. Acute pretreatment with d-butaclamol (0.64 mg/kg, SC), but not with the l-enatiomer, blocked the AIBS. No sham-boxing occurred when d-amphetamine (1 and 5 mg/kg), bromocriptine (10 and 20 mg/kg), piribidel (1, 5, 10, 20 and 40 mg/kg) and TRH (1 and 20 mg/kg) were substituted for apomorphine; in the presence of noise, substitution of piribidel (5, 10, 20 and 40 mg/kg) elicited mild displays of sham-boxing. When apomorphine (1 mg/kg) was substituted for chronically-administered bromocriptine (20 mg/kg) bidirectional circling, but no AIBS, was seen. Apomorphine, when substituted for piribidel or TRH, did not induce circling or the AIBS. Tolerance did not develop to the AIBS over 90 days; 31 days after the final injection, the AIBS could again be elicited by a single dose of apomorphine (1 mg/kg). The behavioral syndrome linked with chronic administration of apomorphine, and the associated reverse tolerance, differentiate apomorphine from the other test compounds. Nevertheless, the partial cross-sensitization between apomorphine and piribidel, and between bromocriptine and apomorphine, provides evidence of common mechanisms at the functional level. The AIBS represents an additional model that may be used in the study of dopamine receptors in vivo.",
keywords = "Apomorphine, Bromocriptine, Chronic administration, Piribidel, Reverse tolerance, Sham-boxing, Tail-vibration, TRH",
author = "Frank Porreca and A. Cowan and Tallarida, {R. J.}",
year = "1982",
month = "1",
doi = "10.1007/BF00430759",
language = "English (US)",
volume = "76",
pages = "70--74",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats

AU - Porreca, Frank

AU - Cowan, A.

AU - Tallarida, R. J.

PY - 1982/1

Y1 - 1982/1

N2 - The dopaminergics, apomorphine (1 mg/kg), bromocriptine (1, 10 and 20 mg/kg), piribidel (5, 20 and 40 mg/kg) and thyrotropin releasing hormone (TRH) (1, 10 and 20 mg/kg), were each injected SC in rats at 09.00 h and 18.00 h daily for at least 20 days. Only apomorphine induced a behavioral syndrome (AIBS) in both male and female rats, characterized by tail-vibration (within 5 days) and a hyperexcitement which included defecation, mounting (in males only), jumping, cliff-jumping, climbing and, after 9-11 days, sham-boxing. Chronically-treated rats were placed, individually, in a small glass cylinder; only those rats on apomorphine displayed an increase in excitement and constant circling, almost exclusively in a counterclockwise direction. Acute pretreatment with d-butaclamol (0.64 mg/kg, SC), but not with the l-enatiomer, blocked the AIBS. No sham-boxing occurred when d-amphetamine (1 and 5 mg/kg), bromocriptine (10 and 20 mg/kg), piribidel (1, 5, 10, 20 and 40 mg/kg) and TRH (1 and 20 mg/kg) were substituted for apomorphine; in the presence of noise, substitution of piribidel (5, 10, 20 and 40 mg/kg) elicited mild displays of sham-boxing. When apomorphine (1 mg/kg) was substituted for chronically-administered bromocriptine (20 mg/kg) bidirectional circling, but no AIBS, was seen. Apomorphine, when substituted for piribidel or TRH, did not induce circling or the AIBS. Tolerance did not develop to the AIBS over 90 days; 31 days after the final injection, the AIBS could again be elicited by a single dose of apomorphine (1 mg/kg). The behavioral syndrome linked with chronic administration of apomorphine, and the associated reverse tolerance, differentiate apomorphine from the other test compounds. Nevertheless, the partial cross-sensitization between apomorphine and piribidel, and between bromocriptine and apomorphine, provides evidence of common mechanisms at the functional level. The AIBS represents an additional model that may be used in the study of dopamine receptors in vivo.

AB - The dopaminergics, apomorphine (1 mg/kg), bromocriptine (1, 10 and 20 mg/kg), piribidel (5, 20 and 40 mg/kg) and thyrotropin releasing hormone (TRH) (1, 10 and 20 mg/kg), were each injected SC in rats at 09.00 h and 18.00 h daily for at least 20 days. Only apomorphine induced a behavioral syndrome (AIBS) in both male and female rats, characterized by tail-vibration (within 5 days) and a hyperexcitement which included defecation, mounting (in males only), jumping, cliff-jumping, climbing and, after 9-11 days, sham-boxing. Chronically-treated rats were placed, individually, in a small glass cylinder; only those rats on apomorphine displayed an increase in excitement and constant circling, almost exclusively in a counterclockwise direction. Acute pretreatment with d-butaclamol (0.64 mg/kg, SC), but not with the l-enatiomer, blocked the AIBS. No sham-boxing occurred when d-amphetamine (1 and 5 mg/kg), bromocriptine (10 and 20 mg/kg), piribidel (1, 5, 10, 20 and 40 mg/kg) and TRH (1 and 20 mg/kg) were substituted for apomorphine; in the presence of noise, substitution of piribidel (5, 10, 20 and 40 mg/kg) elicited mild displays of sham-boxing. When apomorphine (1 mg/kg) was substituted for chronically-administered bromocriptine (20 mg/kg) bidirectional circling, but no AIBS, was seen. Apomorphine, when substituted for piribidel or TRH, did not induce circling or the AIBS. Tolerance did not develop to the AIBS over 90 days; 31 days after the final injection, the AIBS could again be elicited by a single dose of apomorphine (1 mg/kg). The behavioral syndrome linked with chronic administration of apomorphine, and the associated reverse tolerance, differentiate apomorphine from the other test compounds. Nevertheless, the partial cross-sensitization between apomorphine and piribidel, and between bromocriptine and apomorphine, provides evidence of common mechanisms at the functional level. The AIBS represents an additional model that may be used in the study of dopamine receptors in vivo.

KW - Apomorphine

KW - Bromocriptine

KW - Chronic administration

KW - Piribidel

KW - Reverse tolerance

KW - Sham-boxing

KW - Tail-vibration

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=0020043363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020043363&partnerID=8YFLogxK

U2 - 10.1007/BF00430759

DO - 10.1007/BF00430759

M3 - Article

C2 - 6805012

AN - SCOPUS:0020043363

VL - 76

SP - 70

EP - 74

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -